SRS8103775 SAMN17524064 GSM5032761 AML5.ATAC Relapse sample after 1 cycle of nivolumab re-exposure 9606 Homo sapiens bioproject 694429 source_name Peripheral blood tissue blood disease state AML active disease wbc 27.07 sample type C6D1 SRS8103776 SAMN17524063 GSM5032762 AML6.ATAC Relapse sample 3 months after unsuccessful re-exposure to nivolumab 9606 Homo sapiens bioproject 694429 source_name Peripheral blood tissue blood disease state AML active disease wbc 32.19 sample type Progression SRS8103771 SAMN17524068 GSM5032757 AML1.ATAC Baseline sample 6 months before nivolumab 9606 Homo sapiens bioproject 694429 source_name Peripheral blood tissue blood disease state AML active disease wbc 7.13 sample type Baseline SRS8103772 SAMN17524067 GSM5032758 AML2.ATAC Response sample after 1 cycle of nivolumab 9606 Homo sapiens bioproject 694429 source_name Peripheral blood tissue blood disease state AML active disease wbc 9.35 sample type C2D1 SRS8103773 SAMN17524066 GSM5032759 AML3.ATAC Response sample after 3 cycles of nivolumab 9606 Homo sapiens bioproject 694429 source_name Peripheral blood tissue blood disease state AML active disease wbc 8.44 sample type C4D1 SRS8103774 SAMN17524065 GSM5032760 AML4.ATAC Relapse sample 5 months after response 9606 Homo sapiens bioproject 694429 source_name Peripheral blood tissue blood disease state AML active disease wbc 24.59 sample type Relapse